{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:34:33Z","timestamp":1780565673304,"version":"3.54.1"},"reference-count":80,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3121,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.01267.x","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T01:33:44Z","timestamp":1171503224000},"page":"463-472","source":"Crossref","is-referenced-by-count":48,"title":["Insulin resistance and HIV infection: a review"],"prefix":"10.1155","volume":"61","author":[{"given":"M.","family":"Aboud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Elgalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kulasegaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2007,2,14]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB1|cit1","volume-title":"Reports of Diabetes and Hyperglycaemia in Patients Receiving PI's for the Treatment of HIV. FDA Public Advisory","author":"Murray","year":"1997"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB2|cit2","first-page":"513","volume-title":"Ellenberg and Rifkin's Diabetes Mellitus","author":"Olefsky","year":"1997"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB3|cit3","unstructured":"American Diabetes Association http:\/\/www.diabetes.org\/for-health-professionals-and-scientists\/professionals.jsp"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB4|cit4","unstructured":"Diabetes UK http:\/\/www.diabetes.org.uk\/infocentre\/carerec\/newdiagnotic.htm"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/eje.1.01835","article-title":"Defective glucose and lipid metabolism in HIV infected patients with lipodystrophy involve liver, muscle tissue, and pancreatic beta cells","volume":"152","author":"Haugaard","year":"2005","journal-title":"Eur J Endoc"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2337\/diabetes.51.11.3163","article-title":"Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy","volume":"51","author":"Gan","year":"2002","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/diabetes.52.4.918","article-title":"Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens","volume":"52","author":"Woerle","year":"2003","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1172\/JCI200215626","article-title":"Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy","volume":"110","author":"Behrens","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1172\/JCI10582","article-title":"Signaling pathways in insulin action: molecular targets of insulin resistance","volume":"106","author":"Pessin","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"55147","DOI":"10.1074\/jbc.M410826200","article-title":"A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity","volume":"279","author":"Hertel","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB13|cit13","volume-title":"Proteasome and Glucose Transport Inhibition: a Unifying Hypothesis for the Mechanism of Protease inhibitor Induced Metabolic Disturbances and for the Superior Lipid Profile of Atazanavir","author":"Parker","year":"2003"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitors therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB15|cit15","first-page":"173","article-title":"Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease","volume":"14","author":"De Fonzo","year":"1999","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2006.01267.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1463-1326.1999.0010s1023.x","article-title":"Insulin resistance: an independent risk factor for cardiovascular disease?","volume":"1","author":"Balkau","year":"1999","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/01.CIR.97.10.996","article-title":"Insulin and risk of cardiovascular disease: a meta-analysis","volume":"97","author":"Ruige","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB18|cit18","volume-title":"Insulin Resistance in HIV Lipodystrophy Syndrome","author":"Hadigan","year":"2001"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/diacare.24.3.460","article-title":"Diagnosing insulin resistance in the general population","volume":"24","author":"McAuley","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1464-5491.2002.00745.x","article-title":"The assessment of insulin resistance in man","volume":"19","author":"Wallace","year":"2002","journal-title":"Diabet Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2337\/diacare.25.6.984","article-title":"The performance of a risk score in predicting undiagnosed hyperglycemia","volume":"25","author":"Park","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with HIV infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","article-title":"Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with PI's","volume":"13","author":"Behrens","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB24|cit24","volume-title":"Diabetes and Hypoglycaemia in Patients Receiving PI's. 5th Conference on Retroviruses and Opportunistic Infections","author":"Kernly","year":"1998"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB25|cit25","first-page":"89","volume-title":"The Effects of Anti Retroviral PI's on Serum Lipid and Glucose in HIV Infected Patients","volume":"12","author":"Chang","year":"1998"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB26|cit26","first-page":"91","volume-title":"Hypoglycaemia Associated with PI Therapy","volume":"12","author":"Sala Rodo","year":"1998"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/meta.2002.29999","article-title":"Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution","volume":"51","author":"Meininger","year":"2000","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB28|cit28","first-page":"225","article-title":"Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy","volume":"25","author":"Vigouroux","year":"1999","journal-title":"Diabetes Metab"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/00002030-199910220-00035","article-title":"The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","article-title":"Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level","volume":"8","author":"Nolan","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200305010-00004","article-title":"A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy","volume":"33","author":"Moyle","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB32|cit32","unstructured":"Montaner JS and the 2NN Study Team The 2NN Study: a Randomized Comparative Trial of First Line Antiretroviral Therapy with Regimens Containing Either Nevirapine, Efavirenz or Both Drugs Combined, Together with Stavudine and Lamivudine Poster for IATEC, UNAIDS Collaborating Center http:\/\/www.alianza-vih.com\/info_cientifica\/files\/1327.pdf"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/340863","article-title":"Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy","volume":"35","author":"Estrada","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00002030-199911120-00007","article-title":"Lipodystrophy defined by clinical source in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations","volume":"13","author":"Christeff","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1210\/jcem.86.1.7164","article-title":"Apoprotein C-III and E-containing lipoparticles and are markedly increase in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy","volume":"86","author":"Bonnet","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2796.1999.00615.x","article-title":"Influence of protease inhibitor therapy on lipoprotein metabolism","volume":"246","author":"Berthold","year":"1999","journal-title":"J Intern Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB37|cit37","volume-title":"Lipid Profiles in HIV-infected Patients Before and After Protease Inhibitor Therapy","author":"Wanke","year":"2000"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","article-title":"Effects of ritonavir on lipids and post heparin lipase in normal subjects","volume":"14","author":"Purnell","year":"2000","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/00002030-200105040-00001","article-title":"Metabolic effects of indinavir in healthy HIV-seronegative men","volume":"15","author":"Noor","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effects of lopinavir\/ritonavir in HIV-negative men","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00126334-200106010-00006","article-title":"Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and beta-cell function in HIV-infected patients","volume":"27","author":"Dube","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1097\/00002030-200110190-00018","article-title":"Getting to the HAART of insulin resistance","volume":"15","author":"Nolan","year":"2001","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB43|cit43","volume-title":"Prospective Study of Glucose and Lipid Metabolism in Antiretroviral-naive Subjects Randomized to Receive Nelfinavir, Efavirenz, or Both Combined with Zidovudine\u2003+\u2003Lamivudine (ZDV\u2003+\u20033TC) or Didanosine\u2003+\u2003Stavudine: A5005s, a Substudy of ACTG 384","author":"Dub\u00e9","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB44|cit44","volume-title":"The Effect of Atazanavir vs Lopinavir\/ritonavir on Insulin-stimulated Glucose Disposal Rate in Healthy Subjects","author":"Noor","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB45|cit45","first-page":"L26","article-title":"Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily each with fixed-dose zidovudine\u2003+\u2003lamivudine","volume":"7","author":"Sension","year":"2002","journal-title":"Antivir Ther"},{"issue":"Suppl. 4","key":"10.1111\/j.1742-1241.2006.01267.x-BIB46|cit46","first-page":"49","article-title":"Atazanavir: absence of serum lipid changes after 48\u2003weeks of treatment in therapy-na\u00efve HIV-positive subjects","volume":"6","author":"Gatell","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effect of lopinavir\/ritonavir in HIV-negative men","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB48|cit48","volume-title":"Prevalence and Incidence of Pre-diabetes and Diabetes in the Multicenter AIDS Cohort Study","author":"Brown","year":"2004"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2337\/diacare.25.5.829","article-title":"The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and lifestyle study","volume":"25","author":"Dunstan","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Panel Treatment III)","volume":"285","author":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.mca.0000076512.29238.2a","article-title":"The insulin resistance syndrome and coronary artery disease","volume":"14","author":"Kendal","year":"2003","journal-title":"Coron Artery Dis"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.98.5.398","article-title":"Hyperinsulinaemia predicts coronary heart disease risk in healthy middle-aged men: the 22\u2003year follow-up results of the Helsinki Policemen Study","volume":"98","author":"Pyorala","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJM199604113341504","article-title":"Hyperinsulinaemia as an independent risk factor for ischaemic heart disease","volume":"334","author":"Despres","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.86.2.7410","article-title":"Increased PAI1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance","volume":"86","author":"Hadigan","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199503093321003","article-title":"Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group","volume":"332","author":"Thompson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/01.CIR.88.5.2030","article-title":"Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up","volume":"88","author":"Jansson","year":"1993","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(94)90064-7","article-title":"Prospective study of endogenous tPA and risk of stroke","volume":"343","author":"Ridker","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.STR.31.1.26","article-title":"Tissue plasminogen activator, plasminogen activator inhibitor 1, and tissue plasminogen activator\/plasminogen activator inhibitor-1 complex as risk factors for the development of first stroke","volume":"31","author":"Johansson","year":"2000","journal-title":"Stroke"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJM200006153422406","article-title":"Plasminogen activator inhibitor-1 and coronary artery disease","volume":"342","author":"Kohler","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.283.2.221","article-title":"Hyperinsulinaemia, hyperglycaemia, and impaired hemostasis: the Framingham Offspring study","volume":"283","author":"Meigs","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.289.14.1799","article-title":"Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial","volume":"289","author":"Esposito","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.amjmed.2005.03.039","article-title":"The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity","volume":"118","author":"Barnard","year":"2005","journal-title":"Am J Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.lfs.2004.08.028","article-title":"Modulatory role of food, feeding regime and physical exercise on body weight and insulin resistance","volume":"76","author":"Kretschmer","year":"2005","journal-title":"Life Sci"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.2337\/diacare.26.12.3230","article-title":"The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity","volume":"26","author":"Lindstrom","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB67|cit67","unstructured":"British HIV Association Guidelines 2005 http:\/\/www.bhiva.org\/guidelines\/2005\/HIV\/HIV05frameset.html"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin: new understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/archinte.163.21.2594","article-title":"Risk of fatal and non fatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"163","author":"Salpeter","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-200402200-00013","article-title":"Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients","volume":"18","author":"Driscoll","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/diacare.22.6.908","article-title":"Effect of troglitazone on body fat distribution in type 2 diabetic patients","volume":"22","author":"Mori","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2006.01267.x-BIB76|cit76","first-page":"S195","article-title":"A randomized, double-blind, placebo-controlled study of rosiglitazone for patients with HIV lipodystrophy","volume":"8","author":"Hadigan","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00126334-200210010-00006","article-title":"Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study","volume":"31","author":"Gelato","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2006.01267.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis","volume":"96","author":"Caldwell","year":"2001","journal-title":"Am J Gastroenterol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.01267.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.01267.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T23:39:38Z","timestamp":1707608378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.01267.x"}},"subtitle":["IR and HIV infection"],"short-title":[],"issued":{"date-parts":[[2007,2,14]]},"references-count":80,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01267.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2,14]]}}}